Menu
Věda a výzkum

Publikace

Souhrn publikací našich původních prací či ve spolupráci za posledních sedm let.

2017

Jaruskova M1,2, Curik N1,3, Hercog R4, Polivkova V1,5, Motlova E1, Benes V4, Klamova H1,2,6, Pecherkova P1, Belohlavkova P6,7, Vrbacky F7, Machova Polakova K8,9,10. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment. J Exp Clin Cancer Res. 2017 Apr 18;36(1):55. doi: 10.1186/s13046-017-0523-3.

Lenka Hovorkova, Marketa Zaliova, Nicola C. Venn, Kirsten Bleckmann, Marie Trkova, Eliska Potuckova, Martina Vaskova, Jana Linhartova, Katerina Machova Polakova, Eva Fronkova, Walter Muskovic, Jodie E. Giles, Peter J. Shaw, Gunnar Cario, Rosemary Sutton, Jan Stary, Jan Trka and Jan Zuna. Monitoring of childhood ALL using _BCR-ABL1_ genomic breakpoints identifies a subgroup with CML-like biology. Blood. 2017: blood-2016-11-749978; doi: https://doi.org/10.1182/blood-2016-11-749978

2016

Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0

Toman O, Kabickova T, Vit O, Fiser R, Polakova KM, Zach J, Linhartova J, Vyoral D, Petrak J. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target. Oncol Rep. 2016 Sep;36(3):1258-68. doi: 10.3892/or.2016.4945. Epub 2016 Jul 18

Zemanová K., Žižková H., Jurček T., Dvořáková D., Zach J., Polívková V., Vlčanová K., Divoká M., Křupková L., Hrochová K., Karas M., Machová Poláková K. Chronická myeloidní leukemie – standardizace molekulárního monitorování hladiny transkriptů BCR-ABL1 v České republice. Transfuze Hematol. Dnes, 22, 2016, No. 1, p. 56-64

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S. Development and evaluation of a secondary reference panel for BCR-ABL1 quantitation on the International Scale. Leukemia. 2016 Apr 25. doi: 10.1038/leu.2016.90. [Epub ahead of print]

Preuner S, Barna A, Frommlet F, Czurda S, Konstantin B, Alikian M, Machova Polakova K, Sacha T, Richter J, Lion T, Gabriel C. Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches. Int J Mol Sci. 2016 Apr 29;17(5). pii: E642. doi: 10.3390/ijms17050642.

Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, Zach J, Novak M, Marinov I, Soverini S, Faber E, Machova Polakova K. Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. PLoS One. 2016 May 23;11(5):e0155959. doi: 10.1371/journal.pone.0155959. eCollection 2016.

Soverini S, De Benedittis C, Papayannidis C, Machova Polakova K, Venturi C, Russo D, Bresciani P, Iurlo A, Mancini M, Vitale A, Chiaretti S, Foà R, Abruzzese E, Sorà F, Kohlmann A, Haferlach T, Baccarani M, Cavo M, Martinelli G. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. Leukemia. 2016 Feb 12. doi: 10.1038/leu.2016.17. [Epub ahead of print]

Soverini S, De Benedittis C, Machova Polakova K, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget. 2016 Mar 9. doi: 10.18632/oncotarget.8010. [Epub ahead of print]

2015

Linhartova J, Hovorkova L, Soverini S, Benesova A, Jaruskova M, Klamova H, Zuna J, Machova Polakova K. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. Mol Cancer. 2015 Apr 18;14:89. doi: 10.1186/s12943-015-0363-8.

Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015 May;29(5):999-1003.

Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, Martinelli G, Stopka T, Ernst T, Hochhaus A, Kohlmann A, Soverini S. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015 May;141(5):887-99.

2014

Simona Soverini , Caterina De Benedittis , Katerina Machova Polakova , Gianantonio Rosti , Michele Baccarani and Giovanni Martinelli. BCR-ABL1 compound mutants in Philadelphia chromosome-positive (Ph+) leukemias: hot or not?  E-letter to July 3, 2014; Blood: 124 (1).

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, et al. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia. 2014 Jul 18. doi: 10.1038/leu.2014.217. [Epub ahead of print].

2013

Machova Polakova K, Koblihova J, Stopka T. Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep. 2013 Mar;8(1):28-36.

Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, et al.Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013 Aug 29;122(9):1634-48.

Pavlík, T.; Janoušová, E.; Mayer, J.; Indrák, K.; Jarošová, M.; Klamová, H.; Žáčková, D.; Voglová, J.; Faber, E.; Karas, M.; Machová Poláková, K.; et al.. Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications. American journal of hematology. 2013, vol. 88, no. 9, s. 790-797.

Žáčková, D.; Klamová, H.; Mužík, J.; Cmunt, E.; Ráčil, Z.; Machová Poláková, K.; Dvořáková, D.; Jurček, T.; Rázga, F.; Cetkovský, P.; Dušek, L.; Mayer, J. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for chronic myeloid leukemia patients treated in three different hospitals compare well with results achievable in formal clinical trials. Leukemia & lymphoma. 2013, vol. 54, no. 10, s. 2310-2313.

Klamová H, Poláková KM, Mužík J, Ráčil Z, Záčková D, et al. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels. Cancer Med. 2013 Apr;2(2):216-25.

2012

Kramarzová, K.; Stuchlý, J.; Willasch, A.; Gruhn, B.; Schwarz, J.; Čermák, J.; Machová Poláková, K.; Fuchs, O.; Starý, J.; Trka, J.; Boublíková, L. Real-time PCR quantification of major Wilms’ tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences. Leukemia. 2012, vol. 26, no. 9, s. 2086–2095.

Machová Poláková K, Zemanová K, Součková M, Broučková A, Klamová H. Molekulární genetika v diagnostic a léčbě chronické myeloidní leukémie.  Vnitr Lek. 2012 Aug;58 Suppl 2:38-45.

Slabý O., Svoboda M, .et al. MikroRNA v onkologii:  Machová Poláková K. MikroRNA u chronické myeloidní leukemie. str.243-252. 2012, Galén, ISBN 978-80-7262-587-1.

2011

Kateřina Machová Poláková, Tereza Lopotová, Hana Klamová, Pavel Burda, Marek Trněný, Tomáš Stopka, Jana Moravcová. Expression pattern of microRNAs associated with CML phases and disease related targets. Molecular Cancer  2011, 10:41.

F. Razga, Z. RacilZ, K. Machova Polakova, L.  Buresova, H. Klamova, D.  Zackova , D. Dvorakova, V. Polivkova, P. Cetkovsky, J. Mayer. The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. Int J Hematol. 2011 Sep;94(3):303-6.

Zdenek Racil, Filip Razga, Katerina Machova Polakova, Lucie Buresova, Vaclava Polivkova, Dana Dvorakova, Daniela Zackova, Hana Klamova, Petr Cetkovsky, Marek Trneny, Jiri Mayer. Assessment of the ATP-binding cassette sub-family B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia:  the role of different cell types. Leuk and Lymph, 2011:52(2):331-334.

Daniela Zackova, Hana Klamova, Ladislav Dusek, Jan Muzik, Katerina Machova Polakova, Jana Moravcova, Tomas Jurcek, Dana Dvorakova, Zdenek Racil, Zdenek Pospisil, Alexandra Oltova, Kyra Michalova, Jana Brezinova, Filip Razga, Michael Doubek, Petr Cetkovsky, Marek Trneny, and Jiri Mayer. Imatinib as the First Line Treatment of Patients with Chronic Myeloid Leukemia Diagnosed in the Chronic Phase: Can We Compare Real Life Data to the Results from Clinical Trials? Am J Hematol. 2011 Mar;86(3):318-21.


Rychlý kontakt

Náměstek pro vědu a výzkum
Tel:+420 221 977 208

Zástupkyně náměstka
Tel:+420 221 977 269
Tel:+420 221 977 364

Sekretariát
Tel:+420 221 977 247

Telefonní seznam ÚHKT


Provozní doba

Ambulance
Po – Pá: 7:00–18:00

Denní nemocnice
Víkendy: 9:00–13:00

Dárci
Po – Pá: 7:00–10:30

Návštěvy
Lůžkové oddělení
Po – Pá: 13:00–18:00

JIP a Transplantační jednotka
Po – Pá: 14:00–17:00

Kudy k nám

map

Ústav hematologie a krevní transfuze
U Nemocnice 2094/1
128 20 Praha 2

Nejbližší stanice metra: Karlovo náměstí (linka B)

Nejbližší stanice tramvaje: Karlovo náměstí (10, 16, 22), Moráň (3, 6, 10, 16, 18, 24)

Nejbližší stanice autobusu: U nemocnice (291), Karlovo náměstí (176)

Jak se k nám dostanete